Auriga Files Advanced Drug-Delivery Patent Application to Significantly Expand Revenues from Proprietary Drug Brands; Platform Technology Strengthens Company's Strategy to Extend Brand Exclusivity in Multibillion-Dollar Pharmaceutical Markets.NORCROSS, Ga. -- Auriga Laboratories, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ARGA ARGA Arkansas Rice Growers Association (North Little Rock, AR) ), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, today announced the filing of a new provisional patent application for a key platform technology that will provide market exclusivity of its proven pharmaceutical brands. The recent filing strengthens Auriga's business model to acquire and develop proprietary brands in the prescription drug prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, marketplace, and then to maximize potential revenues through aggressive and broad intellectual property protection and innovative sales and marketing strategies. The proprietary technology will be used to expand such Auriga brands as the Extendryl(R) line, which currently comprises seven different prescription drug products. Extendryl(R) is one of the Company's popular prescription medication brands targeting the multibillion-dollar marketplace for prescription cough, cold and allergy allergy, hypersensitive reaction of the body tissues of certain individuals to certain substances that, in similar amounts and circumstances, are innocuous to other persons. Allergens, or allergy-causing substances, can be airborne substances (e.g. treatments. "Auriga's expanding library of drug delivery technologies and patents has been developed to strengthen our business model and drive new revenues from already proven brand names," said Philip S. Pesin, Chief Executive Officer of Auriga. "This particular patent application is exciting because it will yield market exclusivity of our popular prescription cold medicine Extendryl." Auriga develops pharmaceutical products based on patented drug delivery technologies that match an understanding of patient physiology with advances in cellular biology cellular biology n. The study of the molecular or chemical interactions of biological phenomena. , material science, and pharmaceutics. Its business strategy has been designed to minimize the capital requirements Capital requirements Financing required for the operation of a business, composed of long-term and working capital plus fixed assets. , risk and product time-to-market through the acquisition and reformulation of undervalued Undervalued A stock or other security that is trading below its true value. Notes: The difficulty is knowing what the "true" value actually is. Analysts will usually recommend an undervalued stock with a strong buy rating. products for extended market exclusivity. Auriga's recently filed patent application, named "Multi-Phase Release Methscopolamine Compositions," covers formulations administering methscopolamine in multi-phasic drug release. In a preferred embodiment em·bod·i·ment n. 1. The act of embodying or the state of being embodied. 2. One that embodies: "The flag is the embodiment, not of sentiment, but of history" , the formulation administers methscopolamine in an immediate release, sustained or delayed release, and pulsed release. In another embodiment, the methscopolamine is released in a gradient gradient In mathematics, a differential operator applied to a three-dimensional vector-valued function to yield a vector whose three components are the partial derivatives of the function with respect to its three variables. The symbol for gradient is ∇. , decreasing the side effects Side effects Effects of a proposed project on other parts of the firm. associated with rapidly elevated blood levels. About Auriga Laboratories(TM) Auriga Laboratories(TM) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities. The Company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The Company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive product portfolio currently includes the Extendryl(R) and Levall(R) families of prescription products, indicated for relief of symptoms associated with a range of acute respiratory diseases Noun 1. respiratory disease - a disease affecting the respiratory system respiratory disorder, respiratory illness adult respiratory distress syndrome, ARDS, wet lung, white lung - acute lung injury characterized by coughing and rales; inflammation of the . Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the Company will seek to acquire and/or in-license additional products and technologies to further grow revenues. For more information, please visit: www.aurigalabs.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/auriga/. For an informational video overview, visit http://www.trilogy-capital.com/tcp/auriga/video.html. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/auriga/quote.html. Forward-Looking Statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Securities and Exchange Commission and other regulatory authorities Noun 1. regulatory authority - a governmental agency that regulates businesses in the public interest regulatory agency administrative body, administrative unit - a unit with administrative responsibilities . Statements regarding the regulatory status and/or regulatory compliance of our products, our ability to secure additional financing, our ability to sustain market acceptance for our products, our dependence on collaborators, our ability to find and execute strategic transactions, or potential exposure to litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , our exposure to product liability claims, and our prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion